Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Biographical Sketch
Current Positions: Dr. Chisolm is currently Vice Chairman of the Lerner Research Institute of Cleveland Clinic, where he is a Professor of Cell Biology. He also holds active secondary professorships in the Cleveland Clinic Lerner College of Medicine (CCLCM) of Case Western Reserve University, Kent State University and Cleveland State University. He is also Director of Cleveland Clinic’s Innovation Management and Conflict of Interest Program.
Education: He received a BS from the University of Pennsylvania (Philadelphia), PhD from the University of Virginia (Charlottesville) and postdoctoral research training from the Karolinska Institute (Stockholm) and Massachusetts Institute of Technology (Cambridge).
Research: Dr. Chisolm has published over 110 scientific articles, most on vascular biology and the cell biology of atherosclerosis. His work and contemporaneous studies from others led to the theory that oxidation of low density lipoprotein, LDL, accelerates atherosclerosis.
His laboratory continues to study oxidized LDL's influence on gene expression, programmed cell death, cell proliferation, pro-coagulation processes and “foam cell” formation. His research funding has come predominantly from multiple grants from the NIH, the American Heart Association and the pharmaceutical industry. Dr. Chisolm received the Research Merit Award from the American Heart Association’s Ohio Valley Affiliate (2001) and a Special Recognition Award for Vascular Biology Research from the AHA’s (national) Council on Arteriosclerosis, Thrombosis and Vascular Biology (2006).
Cleveland Clinic (institutional leadership, service, education): Dr. Chisolm has served on Cleveland Clinic’s Board of Governors and Board of Trustees. He is actively involved in numerous aspects of Cleveland Clinic’s new medical school, the CCLCM. He is co-director of the school’s Basic Science Curriculum and sits on the Admissions, Faculty Appointments and Promotions, Student Promotion and GI Curriculum committees. He is recipient of the 2007 Lerner Research Institute Award for Excellence in Education.
Conflict of Interest: Dr. Chisolm is Director of Cleveland Clinic’s Innovation Management and Conflict of Interest Program, Chairman of the IM&CoI Committee and a member of the Clinic’s Board of Trustees CoI Committee. He played an active role in crafting the Clinic’s current CoI policies. He is on the Steering Committee for the Association of American Medical College Forum on Conflict of Interest in Academe and in 2006 hosted at Cleveland Clinic the annual national meeting of this organization and another national summit on CoI (9/06). He has been on the program planning committees for the Forum’s national meetings sponsored by Johns Hopkins University School of Medicine (9/07) and Mayo Clinic (9/08). He was a member of the joint AAMC-AAU Advisory Committee on Conflicts of Interest in Human Subjects Research that recently published updated CoI guidelines. He is a member of CWRU’s CoI Committee and CWRU’s President’s Committee on CoI Policy Development.
American Heart Association: Dr. Chisolm has served the AHA at the regional and national level in numerous committees, task forces and as an officer. He has, for example, served as a member of the Board of Trustees and Board of Directors of regional affiliates, as the President of the regional affiliate, on multiple research peer-review study sections, including as chairman, at the regional and national level. He is an active member and recent officer of the AHA’s Council on Arteriosclerosis, Thrombosis and Vascular Biology.
NIH and Other National Committees: He has served on multiple NIH committees, including the NHLBI Study Section for Program Projects (Chair), the Metabolism Study Section, and the Data Management and Safety Board for the "Arterial Disease Multiple Intervention Trial". He is a member of multiple professional societies.
Editorial Boards and manuscript review: Dr. Chisolm has served as Associate Editor or on the Editorial Board of American Journal of Physiology: Heart and Circulatory Physiology, Arteriosclerosis, Thrombosis and Vascular Biology, and Journal of Biological Chemistry. He has been an ad hoc reviewer for over forty scientific journals.
Specialty Interests
lipoprotein oxidation, vascular diseases, lipoprotein-cell interactions, atherosclerosis
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 9/17/2012, Dr. Chisolm has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.